Education
About Us
Working with TipRanks
Follow Us
Adaptive Biotechnologies Corp (ADPT)
NASDAQ:ADPT
ADPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.85 - $12.43
Previous CloseN/A
Volume480.81K
Average Volume (3M)2.09M
Market Cap
$1.57B
Enterprise Value$1.14B
Total Cash (Recent Filing)$193.42M
Total Debt (Recent Filing)$86.90M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Aug 05, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding151,916,720
10 Day Avg. Volume1,425,990
30 Day Avg. Volume2,094,194
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue5.99
Enterprise Value/Gross Profit9.81
Enterprise Value/Ebitda-9.54
Forecast
1Y Price Target
$12.40Price Target Upside20.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Coverage ExpansionAdaptive secures its first surveillance monitoring coverage win for clonoSEQ, which could signal similar expansion to other cancer types.
Market PositionADPT is likely to convert more clinical trial customers to use its flagship clonoSEQ MRD test for primary endpoints following a highly positive FDA ODAC meeting vote.
Product PerformanceMRD clinical testing revenue increased by 55% year over year due to a record number of tests performed.
Revenue GrowthThe company showed significant growth in clinical testing and pharma sequencing, supported by milestones recognized in the quarter.
Bears Say
Cash Burn ConcernsAnalyst was concerned about the cash burn from ADPT’s Immune Medicine business and awaited further penetration in MRD.
Valuation ConcernsThe valuation has now aligned with comparable companies, suggesting a possible period of consolidation.
Adaptive Biotechnologies News
ADPT FAQ
What was Adaptive Biotechnologies Corp’s price range in the past 12 months?
Adaptive Biotechnologies Corp lowest stock price was $3.85 and its highest was $12.43 in the past 12 months.
What is Adaptive Biotechnologies Corp’s market cap?
Adaptive Biotechnologies Corp’s market cap is $1.57B.
When is Adaptive Biotechnologies Corp’s upcoming earnings report date?
Adaptive Biotechnologies Corp’s upcoming earnings report date is Aug 05, 2025 which is tomorrow.
How were Adaptive Biotechnologies Corp’s earnings last quarter?
Adaptive Biotechnologies Corp released its earnings results on May 01, 2025. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.292 by $0.092.
Is Adaptive Biotechnologies Corp overvalued?
According to Wall Street analysts Adaptive Biotechnologies Corp’s price is currently Undervalued.
Does Adaptive Biotechnologies Corp pay dividends?
Adaptive Biotechnologies Corp does not currently pay dividends.
What is Adaptive Biotechnologies Corp’s EPS estimate?
Adaptive Biotechnologies Corp’s EPS estimate is -0.24.
How many shares outstanding does Adaptive Biotechnologies Corp have?
Adaptive Biotechnologies Corp has 151,916,720 shares outstanding.
What happened to Adaptive Biotechnologies Corp’s price movement after its last earnings report?
Adaptive Biotechnologies Corp reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.292. Following the earnings report the stock price went up 33.696%.
Which hedge fund is a major shareholder of Adaptive Biotechnologies Corp?
Currently, no hedge funds are holding shares in ADPT
Adaptive Biotechnologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.40 (20.04% Upside)
$12.40 (20.04% Upside)
Blogger Sentiment
Bullish
ADPT Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
132.13%
12-Months-Change
Fundamentals
Return on Equity
-60.96%
Trailing 12-Months
Asset Growth
-17.65%
Trailing 12-Months
Company Description
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
ADPT Company Deck
ADPT Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted robust growth in MRD revenue, improved gross margins, and strategic advancements in payer contracting, along with a significant reduction in cash burn. However, there was a slight decline in Immune Medicine revenue due to expected reductions in Genentech amortization.Read More>ADPT Stock 12 Month Forecast
Average Price Target
$12.40
▲(20.04%Upside)
Technical Analysis
Iovance Biotherapeutics
―
Syndax Pharmaceuticals
―
89bio
―
Pharvaris
―
Immunocore Holdings
―
Ownership Overview
4.46% Insiders
19.56% Mutual Funds
0.23% Other Institutional Investors
59.22% Public Companies and
Individual Investors